Drug General Information
Drug ID	D0V7SO
Former ID	DIB016707
Drug Name	PF-06291874
Indication	Type 2 diabetes [ICD9: 250; ICD10:E11]		Phase 2	[524811]
Company	Pfizer
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Glucagon receptor	Target Info	Antagonist	[551494]
KEGG Pathway	Neuroactive ligand-receptor interaction
	Glucagon signaling pathway
Reactome	Glucagon signaling in metabolic regulation
	G alpha (q) signalling events
	G alpha (s) signalling events
	Glucagon-type ligand receptors
WikiPathways	GPCRs, Class B Secretin-like
	Gastrin-CREB signalling pathway via PKC and MAPK
	Integration of energy metabolism
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 524811	ClinicalTrials.gov (NCT02175121) Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
Ref 551494	Clinical pipeline report, company report or official report of pfizer.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.